Next Generation Replicon RNA vaccines for a range of challenging diseases

Tiba Biotech emerged in 2018 from a four-year multi-lab research initiative between the Massachusetts Institute of Technology’s Koch Institute, the Whitehead Institute, and Boston Children’s Hospital. We leverage a proprietary replicon RNA technology platform to develop safer, affordable vaccines and therapeutics for both human and animal health.